IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

This trial is testing whether adding IN10018 (an experimental drug) to a standard chemotherapy drug called pegylated liposomal doxorubicin (PLD) improves outcomes for women with platinum-resistant recurrent ovarian cancer — cancer that came back within 6 months of platinum-based chemotherapy. **You may be eligible if...** - You are a woman aged 18 or older - You have confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer - Your cancer progressed during or within 6 months of platinum-based chemotherapy - You have received no more than 3 prior lines of treatment - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - Your cancer is primary platinum-refractory (progressed during or within 4 weeks of your very first platinum treatment) - You have had more than 3 prior lines of systemic therapy - You have certain serious heart conditions or uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.